{
    "clinical_study": {
        "@rank": "109165", 
        "arm_group": [
            {
                "arm_group_label": "retrospective cohort", 
                "description": "retrospective follow-up of patients treated since 2006"
            }, 
            {
                "arm_group_label": "prospective cohort", 
                "description": "patients treated over a 5-year period from January 15, 2013 to December 31, 2017 and followed for at least one year thereafter"
            }
        ], 
        "brief_summary": {
            "textblock": "The investigators will learn from this study if the CyberKnife radiosurgery (CK RS)\n      treatment of patients with 1-3 versus 4 or more brain metastases results in the same overall\n      survivals. The importance of this new knowledge will be to determine the treatment efficacy\n      of CK RS with 1-3 versus 4 or more brain metastases. The outcome of this trial would give\n      data to support either the continuation or modification of the CK RS treatment of patients\n      with brain metastases."
        }, 
        "brief_title": "Phase I Compare OS in Post-CyberKnife Radiosurgery Tx in 1-3 VS 4 or More Brain Metastases", 
        "condition": "Brain and Nervous System", 
        "condition_browse": {
            "mesh_term": "Neoplasm Metastasis"
        }, 
        "detailed_description": {
            "textblock": "This is registry-based cohort study of patients with brain metastases treated at Stanford\n      University Medical Center (SUMC) with CyberKnife radiosurgery (CK RS). It has two\n      components: (1) a retrospective follow-up of patients treated since 2006, and (2) the\n      accrual of a new cohort of patients treated over a 5-year period from January 15, 2013 to\n      December 31, 2017 and followed for at least one year thereafter. The primary aim of this\n      study is to estimate the effect of the number of brain tumor metastases on survival after\n      adjusting for known risk factors for mortality."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. the presence of a tumor metastasis or tumor metastases to the brain as manifested by\n             the neurological examination and visibility of the metastatic lesion(s) on MRI and CT\n             scans\n\n          2. a Karnofsky performance status (KPS) score of greater than or equal to 60.\n\n        Exclusion Criteria:\n\n        The exclusion criteria are the converse of the above, i.e. patients without a brain tumor\n        metastasis or brain tumor metastases or a KPS of less than 60."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "95 Years", 
            "minimum_age": "21 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with all types of primary cancers which have metastasized  to the brain."
            }
        }, 
        "enrollment": {
            "#text": "1000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01778764", 
            "org_study_id": "BRN0022", 
            "secondary_id": "26173"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 24, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Stanford", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94305"
                }, 
                "name": "Stanford University Cancer Institute"
            }, 
            "investigator": {
                "last_name": "Steven Chang", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "2", 
        "official_title": "A Comparison of Overall Survival Post-CyberKnife Radiosurgery Treatment of Patients With 1-3 Versus 4 or More Brain Metastases", 
        "overall_contact": {
            "email": "sdchang@stanford.edu", 
            "last_name": "Steven Chang", 
            "phone": "650-723-5573"
        }, 
        "overall_official": {
            "affiliation": "Stanford University", 
            "last_name": "Steven Chang", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Overall survival", 
            "safety_issue": "No", 
            "time_frame": "until death or the end of follow-up, whichever comes first."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01778764"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Stanford University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Stanford University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Observational Model: Cohort", 
        "study_type": "Observational", 
        "verification_date": "January 2013"
    }
}